{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-124500","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2025-12-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.158705+00:00","generated_at":"2026-05-16T12:11:42.011348+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Acura Pharmaceuticals extends debt maturity, secures additional loans from AD Pharma, warns of possible shutdown","bullets":["Received $300k in three new loans from Abuse Deterrent Pharma, raising principal to $9,294,279 at 5.25% interest.","Amended license agreement for LTX-03, extending FDA NDA acceptance deadline from Dec 31, 2025 to June 30, 2026.","Extended maturity of secured promissory note and warrant expiration to June 30, 2026.","AD Pharma now directly owns approximately 65% of Acura's outstanding common stock.","Company warns it may scale back operations or seek bankruptcy protection if additional financing is not obtained by end of December 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-124500","json":"https://secwatch.observer/filing/0001104659-25-124500.json","markdown":"https://secwatch.observer/filing/0001104659-25-124500.md","text":"https://secwatch.observer/filing/0001104659-25-124500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/tm2534375d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T12:11:42.011348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4103679ce4657786368aaeea66b08f031583ee1d","claim":"ACURA PHARMACEUTICALS, INC incurred loan of $100,000 loans with Abuse Deterrent Pharma, LLC at 5.25%.","evidence_excerpt":"On each of November 12, 2025, November 21, 2025 and December 12, 2025, we received $100,000 loans from Abuse Deterrent Pharma, LLC (“AD Pharma”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$100,000 loans"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Event","value":"incurrence"}]},{"claim_id":"f0ab22ed3946179c9a604e24d8a9eba68c6392ce","claim":"ACURA PHARMACEUTICALS, INC amended debt with Abuse Deterrent Pharma, LLC maturing June 30, 2026.","evidence_excerpt":"This amendment #7 has an effective date of December 22, 2025 and changes the maturity date of the Amended Note from December 31, 2025 to June 30, 2026, at which time all principal and interest is due.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Maturity","value":"June 30, 2026"},{"label":"Event","value":"amendment"}]},{"claim_id":"3a02180e3012748990185131d43365c6781ab4a7","claim":"ACURA PHARMACEUTICALS, INC entered into Note with Abuse Deterrent Pharma, LLC (AD Pharma) valued at $100,000 loans (effective 2025-11-12).","evidence_excerpt":"On each of November 12, 2025, November 21, 2025 and December 12, 2025, we received $100,000 loans from Abuse Deterrent Pharma, LLC (“AD Pharma”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC (AD Pharma)"},{"label":"Value","value":"$100,000 loans"},{"label":"Effective","value":"2025-11-12"}]},{"claim_id":"a92da4a1cb5ad48d8016d41522f06ca2fe1051d5","claim":"ACURA PHARMACEUTICALS, INC amended Amended Agreement with AD Pharma (effective 2025-12-22).","evidence_excerpt":"This amendment #13 has an effective date of December 22, 2025 and extends the FDA’s acceptance date of a New Drug Application (“NDA”) for LTX-03 from December 31, 2025 to June 30, 2026 (“NDA Acceptance Date”) (“Amended Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"AD Pharma"},{"label":"Effective","value":"2025-12-22"}]},{"claim_id":"ab4691481fb61a38049b436449b0122db942f71a","claim":"ACURA PHARMACEUTICALS, INC amended Warrant with AD Pharma (effective 2025-12-22).","evidence_excerpt":"nd December 12, 2025, we received $100,000 loans from Abuse Deterrent Pharma, LLC (“AD Pharma”). These loans combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"AD Pharma"},{"label":"Effective","value":"2025-12-22"}]},{"claim_id":"caf906a77015690818bd5fb1135c935bcf77cbe1","claim":"ACURA PHARMACEUTICALS, INC amended Amended Note with AD Pharma (effective 2025-12-22).","evidence_excerpt":"This amendment #7 has an effective date of December 22, 2025 and changes the maturity date of the Amended Note from December 31, 2025 to June 30, 2026, at which time all principal and interest is due.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"AD Pharma"},{"label":"Effective","value":"2025-12-22"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}